While overdiagnosis and overtreatment are major harms in prostate cancer screening, use of an upper age limit, including risk stratification after baseline PSA, high-quality MRI scanning, and other complementary tests will significantly reduce overdiagnosis and improve the harm-to-benefit ratio. This evidence concerns the gene KLK3 and prostate carcinoma.